1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6158EF2C4743E140800258CC80040DC1F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-maximizing-impact-hematology-analytics-insights-teams-scaling-excellence-innovation-coes?opendocument
18
19opendocument
2018.97.14.91
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Market Research, Analytics and Forecasting » Analytics

Maximizing the Impact of Hematology Analytics & Insights Teams: Scaling Excellence with Advanced Analytics and Innovation CoEs

ID: 5890


Features:

19 Info Graphics

20 Data Graphics

720+ Metrics

16 Narratives


Pages/Slides: 46


Published: 2025


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Maximizing the Impact of Hematology Analytics & Insights Teams: Scaling Excellence with Advanced Analytics and Innovation CoEs”

STUDY OVERVIEW

As the hematology landscape grows increasingly complex, organizations that embed advanced analytics and cultivate Innovation Centers of Excellence are redefining the role of Analytics & Insights (A&I) within the enterprise. Rather than serving as reactive reporting functions, these teams are driving proactive, data-driven strategies that inform clinical development, accelerate commercialization, and shape market access with greater precision.


This benchmarking study provides senior executives with a clear view into how best-in-class hematology A&I organizations scale excellence through advanced capabilities and innovation frameworks. It demonstrates how forward-looking leaders are using next-generation analytics to unify insights, strengthen cross-functional collaboration, and enhance engagement with internal and external stakeholders. The result is a reimagined A&I function that not only keeps pace with scientific advances but also improves patient outcomes.

KEY TOPICS

  • High-value analytics, methodologies, platforms and outsourcing approaches
  • Streamlining market research via advanced analytics
  • Innovation centers of excellence: Usage, staffing, services and alignment

KEY METRICS

  • Analytic frameworks and methodologies leveraged by Hematology A&I groups for distinct operational objectives
  • High-value analytics projects supporting brand, HEOR, and other key internal partner teams
  • Approaches to balancing internal versus outsourced resources for hematology analytics projects
  • Insource vs. outsource resourcing strategies for specific analytic processes and advanced methodologies
  • Use of analytics as an alternative to traditional market research in hematology
  • Most utilized analytics and reporting platforms
  • Adoption of innovation CoEs to scale expertise and transformation
  • Relationship between innovation CoE (or similar department) and Analytics & Insights groups
  • Headcount and resource commitments dedicated to hematology-focused CoEs or equivalent structures
  • Effective services delivered by innovation CoE (or similar groups) to enhance organizational agility and transformation
  • Professional skills and experiential backgrounds required for talent within innovation CoEs or similar departments

SAMPLE KEY FINDINGS

  • Growing Prevalence of CoEs Among Mid-Sized and Large Pharma: 30% of surveyed hematology companies have established a designated Innovation Center of Excellence (CoE), - with plans to add these CoEs in the next 1-2 years - while most do not have an Excellence team yet.

METHODOLOGY

Best Practices, LLC engaged 12 Analytics & Insights leaders across 12 leading biopharma organizations with a focus on the hematology segment. This study includes segmentation by company size (mid vs. large pharma) and features deep-dive interviews for added qualitative insights. Notably, over 33% of benchmark participants serve at the director-level or above.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Consulting; Research; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
AstraZeneca; Bayer; Biotest AG; Decode Consulting; Janssen; Lonza Inc.; MEDiSTRAVA; Momenta; Novartis; Sanofi; Takeda Pharmaceuticals; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.